Popularity #2,966Earnings are out
BlossomHill Therapeutics (BLSM)
Develops oral small-molecule cancer therapies for EGFR, CLK and KRAS targets.
$22.38
vs last close−2.88 (−11.39%)
In millions of USD, except per-share figures
| In millions | Q1 FY25Mar 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|
| 11 | 22 | 25 | |
| Research & development | 10 | 20 | 21 |
| 2 | 2 | 3 | |
| General & administrative | 2 | 2 | 3 |
| Operating income | −11 | −22 | −25 |
| 1 | 1 | 1 | |
| Interest income | 1 | 1 | 0 |
| Income before tax | −10 | −21 | −24 |
| Net income from continuing operations | −10 | −21 | −24 |
| Net income | −10 | −21 | −24 |
| EPS, basic | −$0.36 | −$0.72 | −$8.75 |
| EPS, diluted | −$0.36 | −$0.72 | −$8.75 |
| Weighted average shares, basic | 29 | 29 | 27 |
| Weighted average shares, diluted | 29 | 29 | 27 |
| EBITDA | −11 | −22 | −25 |
| Depreciation & amortization | 0 | 0 | 0 |
| EBIT | −11 | −22 | 0 |